.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Novartis
Julphar
UBS
AstraZeneca
Express Scripts
Queensland Health
Daiichi Sankyo
Mallinckrodt
Covington

Generated: September 24, 2017

DrugPatentWatch Database Preview

DARIFENACIN HYDROBROMIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Darifenacin Hydrobromide, and what generic Darifenacin Hydrobromide alternatives are available?

Darifenacin Hydrobromide is a drug marketed by Torrent Pharms Ltd, Aurobindo Pharma Ltd, Jubilant Generics, Cipla Ltd, and Anchen Pharms. and is included in five NDAs.

The generic ingredient in DARIFENACIN HYDROBROMIDE is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.

Summary for Tradename: DARIFENACIN HYDROBROMIDE

Patents:0
Applicants:5
NDAs:5
Suppliers / Packagers: see list7
Bulk Api Vendors: see list41
Clinical Trials: see list78
Patent Applications: see list1,358
Drug Prices:see details
DailyMed Link:DARIFENACIN HYDROBROMIDE at DailyMed

Pharmacology for Tradename: DARIFENACIN HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Torrent Pharms Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL205209-001Nov 17, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Cipla Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL207664-001Sep 1, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL206743-002Sep 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Cipla Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL207664-002Sep 1, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Torrent Pharms Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL205209-002Nov 17, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL206743-001Sep 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Jubilant Generics
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL205550-002Oct 12, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Jubilant Generics
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL205550-001Oct 12, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Anchen Pharms
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL091190-002Mar 13, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Anchen Pharms
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL091190-001Mar 13, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Harvard Business School
Cerilliant
Fish and Richardson
Healthtrust
Julphar
AstraZeneca
US Department of Justice
Boehringer Ingelheim
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot